公开(公告)号：US20220259179A1

公开(公告)日：2022-08-18

申请号：US17621851

申请日：2020-06-29

Applicant: UCB Biopharma SRL

Inventor： Ali Ates ,  David Skolc

IPC: C07D401/06

Abstract: The present invention relates to compound according to formula (I), (I) which is a positive allosteric modulator of D1 and accordingly of benefit as pharmaceutical agent for the treatment of diseases in which D1 receptors play a role.

公开(公告)号：US20240083925A1

公开(公告)日：2024-03-14

申请号：US18267946

申请日：2021-12-16

Applicant: UCB Biopharma SRL

Inventor： Ali Ates ,  Celal Ates ,  Laurent Provins

IPC: C07F9/6558 ,  C07D401/06

CPC classification number: C07F9/65583 ,  C07D401/06

Abstract: The present invention relates to a prodrug of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone, which prodrug is represented by formula (II).

公开(公告)号：US20240043400A1

公开(公告)日：2024-02-08

申请号：US18265156

申请日：2021-12-01

Applicant: UCB Biopharma SRL

Inventor： Ali Ates ,  Pierre Burssens ,  Adrian Hall ,  Laurent Provins ,  David Skolc ,  Anne Valade

IPC: C07D401/06 ,  C07D217/04 ,  C07D471/04 ,  C07D401/10

CPC classification number: C07D401/06 ,  C07D217/04 ,  C07D471/04 ,  C07D401/10

Abstract: The present invention relates to octahydroisoquinolinyl derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.